Harnessing Machine Learning and AI for Microbial Biomarker Discovery in Clinical Trials

The human gut microbiome plays a crucial role in human health and disease. Its influence has been increasingly linked to the onset and progression of various conditions such as colorectal cancer, Alzheimer’s disease, and Parkinson’s disease. Identifying specific microbial taxa that are consistently associated with these disease states, known as microbial biomarkers, is essential for advancing diagnostics and personalized therapeutics.

However, microbiome datasets are complex, high-dimensional, and variable across studies, making robust biomarker discovery a challenge. Traditional statistical approaches often require extensive manual analysis and may overlook subtle but clinically relevant patterns.

How machine learning is changing the game

Advances in machine learning (ML) and artificial intelligence (AI) have revolutionized the field and now allow researchers to analyze vast microbiome datasets, such as those from fecal microbiome studies, more efficiently and accurately.

  • Supervised learning techniques like support vector machines and random forest classifiers can classify disease-associated microbial signatures.

  • Unsupervised learning methods, such as clustering algorithms, help uncover hidden patterns in the data.

  • Deep learning models, including convolutional neural networks (CNNs) and recurrent neural networks (RNNs), can enhance predictive accuracy even further.

Recently BaseClear launched a validated bioinformatics service that highlights how machine learning models can efficiently process microbiome data, identifying microbial taxa linked to disease states or treatment responses (Pirovano et al., 2025).

Unlike conventional statistical methods, ML algorithms can handle the high dimensionality and complexity of microbiome datasets, identifying patterns and relationships that may be invisible to traditional analyses. With ML-powered AI, researchers can detect subtle microbial shifts that may serve as early disease indicators or potential therapeutic targets.

We validated our approach using publicly available 16S rRNA gene and shotgun metagenomic datasets across multiple disease contexts. The ensemble framework demonstrated improved consistency, predictive performance, and resolution (species- or strain-level) compared to individual methods.

By leveraging machine learning, BaseClear helps researchers identify microbial biomarkers with greater precision, supporting the development of next-generation probiotics, pharmaceuticals, and personalized nutrition strategies.

Beyond human health

The expertise in AI-driven microbiome analytics ensures that clinical trials and research projects benefit from the latest advancements in computational biology, making it easier to translate microbiome insights into actionable clinical applications.

Similar to the human gut, microbial biomarkers can be identified in soil or rhizospheres that can signal ecosystem health or plant disease. Likewise, the pipeline can be applied in livestock or aquaculture to monitor health, growth, and disease resistance based on gut microbial signatures.

The road ahead

Machine learning in microbiome research is rapidly evolving. Microbiome analysis increasingly relies on machine learning-driven microbiome analytics to assess clinical trials, animal trials and environmental samples. ML models can already:

  • Differentiate responders from non-responders in probiotic or fecal microbiota transplantation trials.

  • Improve patient stratification in clinical studies and optimise therapeutic interventions.

  • Reduce false positives in biomarker discovery, ensuring that identified microbial markers are robust and clinically relevant.

Challenges remain, including data standardization, model interpretability, and the need for larger, well-annotated datasets. However, as ML models improve and gain access to more high-quality clinical data, their potential to revolutionize microbiome research continues to grow. The integration of AI and machine learning in clinical microbiome studies is not just a technological upgrade, it is a paradigm shift that is transforming how we understand and leverage the gut microbiome for human health.

BaseClear’s Key Microbiome Pipeline is now available as a validated service. Contact us at info@baseclear.nl to have your data analysed by our experts.

📄 Read the full open-access publication: Application of Machine Learning Tools for data mining of microbiome data: detection of Key Microbial Biomarkers.

Related items